Earnings Call · Q2 FY2026·2026-02-03

Q2 26EPS +53.06%·Rev n/aQ1 26EPS +52.63%·Rev n/aQ4 25EPS -100.00%*·Rev n/aQ3 25EPS +100.00%*·Rev n/a⚠ consensus missing

AYTU BIOPHARMA, INC AYTU

Robert Blum — Investor Relations

Josh Disbrow — Chief Executive Officer

Ryan Selhorn — Chief Financial Officer

−10.3%1d on move date−9.8% vs SPY3d−8.8%5d−11.8%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more AYTU calls or request research access.

More AYTU calls Browse calls Request research access